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The M HC class-I binding affinity of an epitope is an impor­
tant param eter determining the immunogenicity of the pep- 
tide-M HC complex. In order to improve the immunogenidty 
of an epitope derived from melanocyte lineage-specific anti­
gen gplOO, we  performed amino-acid substitutions within the 
epitope and assayed both HLA-A*0201 binding and CTL  
recognition. Anchor replacements towards the HLA-A*020I 
peptide-binding m otif gave rise to  peptides with higher 
H LA -A *020I binding capacity compared to the wild-type 
epitope. In addition, several of the gplOO 154-162 epitope- 
analogues were more efficient at target-cell sensitization for 
lysis by anti-gplOO 154-162 C TL compared to the wild-type 
epitope. These altered gplOO 154-162 epitopes were subse­
quently tested for their capacity to induce CTL responses in 
vivo using HLA-A*020 l/K b transgenic mice, and in vitro using 
H LA -A *020I + donor-derived lymphocytes. Interestingly, the 
peptide-specific C TL  obtained, which were raised against the 
different gplOO 154-162 epitope-analogues, displayed cross­
reactivity with target cells endogenously processing and 
presenting the native epitope. These data demonstrate that 
altered epitopes can be exploited to elicit native epitope- 
reactive CTL. The use of epitope-analogues with improved 
immunogenicity may contribute to the development of CTL- 
epitope based vaccines in viral disease and cancer. Int. J. 
Cancer, 70:302-309, 1997.
€> 1997 Wiley-Liss, Inc.
Cytotoxic T cells recognize short peptide fragments of 9-11 
amino acids in length, which are presented in the antigen-binding 
groove of MHC class-I molecules. These peptides are usually 
derived from intracellular protein pools and associate in the lumen 
of the endoplasmic reticulum with MHC class-I heavy-chain and 
p2-microglobulin molecules, after which the MHC-peptide com­
plex is transported to the cell surface. Despite the presence of many 
putative antigenic peptides within the same antigen, only a few 
peptides are selected for recognition by CTL.
A major parameter determining cell-surface presentation of a 
given peptide is the affinity of the peptide for MHC class-I 
molecules. Analysis of HLA-A*0201-restricted epitopes recog­
nized by anti-viral CTL demonstrated that the majority of these 
peptides bind to HLA-A*0201 with high affinity. Furthermore, 
immunogenicity analysis of motifs containing potential epitopes, 
using HLA-A*0201 transgenic mice, revealed that a threshold 
MHC class-I affinity was required for a peptide to elicit a CTL 
response (Sette etal, 1994). In addition to the MHC class-I binding 
affinity, stability of peptide-MHC complexes at the cell surface 
contributes to the immunogenicity of a CTL epitope (van der Burg 
et a l , 1996). Consequently, MHC class-I binding affinity and 
stability of peptide-MHC complexes are important criteria in the 
selection of specific peptide determinants for development of 
CTL-epitope-based therapeutic vaccines.
Recently, a number of antigens have been identified as targets for 
anti-melanoma CTL. Using a genetic approach, Boon and col­
leagues identified the tumor-specific antigens MAGE-1 and -3 as 
well as the melanocyte-lineage-specific antigen tyrosinase (Van 
den Eynde and Brichard, 1995). Similarly, we identified the gplOO 
melanocyte-specific protein as a target antigen for melanoma 
tumor-infiltrating lymphocytes (Bakker et al, 1994). Recently, 2 
other melanocyte differentiation antigens, Melan-A/MART-1 and
gp75, were identified as target antigens for anti-melanoma CTL 
(Van den Eynde and Brichard, 1995). Eight HLA-A*0201 re­
stricted epitopes derived from these antigens have now been 
characterized, displaying varying affinities for HLA-A*0201 
(Kawakami et al, 1995; Bakker et a l , 1995b; Van den Eynde and 
Brichard, 1995).
In the present study, we closely examined one of the HLA- 
A*0201 presented epitopes derived from the melanocyte differen­
tiation antigen gplOO that does not strictly follow the common 
HLA-A*0201 peptide-binding motifs. In an attempt to improve the 
immunogenicity of the gplOO 154-162 epitope, we performed 
amino-acid substitutions within the epitope to increase HLA- 
A*0201 binding capacity. We demonstrate that epitope analogues 
allow the induction of peptide-specific CTL displaying cross­
reactivity with target cells endogenously processing and presenting 
the native epitope. Usage of epitope analogues with improved 
immunogenicity may contribute to the development of CTL- 
epitope based vaccines in chronic viral disease and cancer.
m a t e r ia l  a n d  m e t h o d s
Cell culture
The HLA~A1|:0201 + melanoma line BLM was cultured as 
described previously (Bakker et al, 1994). TIL 1200 lymphocytes 
and the melanoma lines Mel 624 and Mel 397 were a kind gift from 
Dr. Y. Kawakami (National Cancer Institute, National Institutes of 
Health, Bethesda, MD) and were cultured as reported previously 
(Kawakami et al, 1992). T2 cells and HLA-A*020i+ B lympho- 
blastoid JY cells were maintained in Iscove’s medium (GIBCO, 
Paisley, UK) supplemented with 5% FCS (BioWhittaker, Verviers, 
Belgium). Jurkat A*0201/Kb cells expressing the HLA-A*0201/Kb 
chimeric molecule were cultured in Iscove’s medium with 5% FCS 
supplemented with 0.8 mg/ml G4I8 (GIBCO).
HLA-A *0201+ lymphocytes
Healthy Caucasian volunteers were HLA-A2 phenotyped by 
flow cytometry using MAbs BB7.2 and MA2.1. The donors 
underwent leukapheresis, and PBMC were isolated by Ficoll/ 
Hypaque density gradient centrifugation. The cells were cryopre- 
served in aliquots of 4 X 107 PBMC.
Transgenic mice
HLA-A*0201/Kb transgenic mice were kindly provided by Dr. 
L. Sherman (San Diego, CA, through Harlan Sprague Dawley,
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number: KUN 91245; contract grant number: KUN 91246; contract grant 
sponsor: the Raad Voor Gezondheidsonderzoek; contract grant number: 
PccAO 95-017.
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Nijmegen, The Netherlands. Fax: 31 24 3540339. E-mail: C.Figdor® 
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Indianapolis, IN). Mice were kept under clean conventional 
conditions. The transgenic mice express the product of the HLA- 
A*0201/Kb chimeric gene in which the domain of the heavy 
chain is replaced by the corresponding murine H-2 Kb domain 
while leaving the HLA-A*0201 a t and a 2 domains unaffected 
(Vitiello et al, 1991). This allows the murine CD8 molecule on the 
murine CD8+ T lymphocytes to interact with the syngeneic a 3 
domain of the hybrid MHC class-I molecule.
Peptides
For induction of CTL and chromium-release assays, peptides 
were synthesized with a free carboxy-terminus by Fmoc peptide 
chemistry using an ABIMED multiple synthesizer. All peptides 
were >90% pure as indicated by analytical HPLC. Peptides were 
dissolved in DMSO and stored at -20°C.
Competition-based HLA-A *0201 peptide-binding assay
Peptide binding to HLA~A*0201 was analyzed using HLA- 
A*0201+ JY cells as described previously (van der Burg et al., 
1995). Briefly, mild-acid-treated JY ceils were incubated with 150 
nM fluorescein (FL)-labelled reference peptide 
[FLPSDC(—FL)FPSV] and with several concentrations of competi­
tor peptide for 24 hr at 4°C in the presence of 1.0 \ig!ml 
P2-microglobulin (Sigma, St. Louis, MO). Subsequently, the cells 
were washed, fixed with paraformaldehyde and analyzed by flow 
cytometry. The mean fluorescence (MF) obtained in the absence of 
competitor peptide was regarded as maximal binding and equated 
to 0%; the MF obtained without reference peptide was equated to 
100% inhibition. The percentage inhibition of binding was calcu­
lated using the formula:
[1-(MF 150 nM reference and competitor peptide
— MF no reference peptide)
(MF 150 nM reference peptide — MF no reference peptide)]
X 100%.
The binding capacity of competitor peptides is expressed as the 
concentration needed to inhibit 50% of binding of the FL-labelled 
reference peptide (IC5o).
Measurement of MHC-peptide complex stability at 37°C
Measurement of MHC-peptide complex stability was performed 
as previously described (van der Burg etai, 1996). HLA-A*0201 + 
homozygous JY cells were treated with 10“4 M emetine (Sigma) 
for 1 hr at 37°C to stop de novo synthesis of MHC class-I 
molecules. The cells were then mild-acid-treated and subsequently 
loaded with 200 pM of peptide for 1 hr at room temperature. 
Thereafter, the cells were washed twice to remove free peptide and 
incubated at 37°C for 0, 2, 4 and 6 hr. Subsequently, the cells were 
stained using MAb BB7.2 (Parham and Brodsky, 1981), fixed with 
paraformaldehyde and analyzed by flow cytometry.
CTL induction in HLA-A*0201/Kh transgenic mice
Groups of 3 HLA-A*0201/Kb transgenic mice were injected 
subcutaneously at the base of the tail vein with 100 jug peptide 
emulsified in IFA in the presence of 140 jag of the H-2 I-Ab- 
restricted HBV core-antigen-derived T-helper epitope (128-140; 
sequence TPPAYRPPNAPIL). After 11 days, mice were killed and 
spleen cells (30 X 106 cells in 10 ml) were restimulated in vitro 
with syngeneic irradiated LPS-stimulated B-cell lymphoblasts 
pulsed with the peptide used for immunization (ratio 4:1). At day 6 
of culture, the bulk responder populations were tested for specific 
lytic activity.
HLA-A*0201 + donor-derived CTL induction in vitro
Using thawed PBMC, we generated dendritic cells according the 
procedure of Romani et al (1994) as described (Bakker et al, 
1995a). Before the beginning of culture, dendritic cells were loaded 
with 50 foM of peptide. Autologous CD8+-enriched responder T 
lymphocytes were prepared by allowing thawed PBMC to adhere
for 2 hr and by subsequent partial depletion of the non-adherent 
fraction of CD4+ T cells using the anti-CD4 MAb RIV-7 and sheep 
anti-mouse IgG-coated magnetic beads (Dynal, Oslo, Sweden). At 
the beginning of stimulation, 2 X 10s peptide-loaded DC and 2 X 
106 responder cells were co-cultured per well of a 24-well 
tissue-culture plate (Costar, Badhoevedorp, The Netherlands) in 2 
ml of Iscove’s medium containing 5% pooled human AB+ serum,
103 U/ml IL-6 (Sandoz, Basel, Switzerland) and 5 ng/ml IL-12 
(kindly provided by Dr. M. Gately, Hoffmann-La Roche, Nutley, 
NJ).
On day 8 and day 15, the responder populations were restimu­
lated using peptide-pulsed dendritic cells as stimulator cells. The 
cultures were propagated in medium containing IL-2 (Cetus, 
Emeryville, CA) and IL-7 (Genzyme, Cambridge, MA) at final 
concentrations of 10 U/ml and 5 ng/ml respectively. At weekly 
intervals thereafter the cultures were restimulated using adherent- 
peptide-pulsed PBMC as described (Bakker et al, 1995a). Re­
sponder populations were tested for specific lytic activity after at 
least 4 rounds of re stimulation.
Chromium-release assay
Chromium release assays were performed as described (Bakker 
et a l , 1994). Briefly, I06 target cells were incubated with 100 pCi 
Na251C r0 4 (Amersham, Aylesbury, UK) for 1 hr. Various amounts 
of effector cells were then added to the target cells in triplicate 
wells of U-bottomed microti ter plates (Costar) in a final volume of 
150 pi. In peptide recognition assays, target cells were pre­
incubated with various concentrations of peptide for 30 or 60 min 
at 37°C in a volume of 100 jul prior to the addition of effector cells. 
After 5 hr of incubation, part of the supernatant was harvested and 
its radioactive content was measured. The mean percentage specific 
lysis of triplicate wells was calculated using the formula:
% specific lysis =  [(experimental release -  spontaneous release)
(maximal release -  spontaneous release)]
X 100
RESULTS
Identification of amino-acid residues engaged in HLA~A*0201 
binding and/or TCR interactions for the gpIOO 154-162 epitope
The gpIOO 154-162 epitope has been identified by means of an 
HLA-A1*0201 -restricted TIL line derived from a metastatic mela­
noma, Among a panel of peptides ranging from 8-mers to 11-mers 
located around gpIOO amino acids 155-161, we identified the
T A B L E  I  -  H LA -A *0201 BINDING AND TARGET-CELL SENSITIZATION OF
ALANINE-REPLACEM ENT EPITOPES
gpIOO 154-162 Affinity IC50 ((JM)1 Target-cell lysis by TIL I2002
KTWGQYWQV 1.4 67
ATWGQYWQV 1.3 75
KAWGQYWQV 1.5 64
KTAGQYWQV 6.2 58
KTWAQYWQV 1.6 63
KTWGAYWQV 1.4 9
KTWGQAWQV 0.9 7
KTWGQYAQV 4.3 - 2
KTWGQYWAV 0.5 73
KTWGQYWQA 1.9 76
binding of peptides to HLA-A*0201 was analyzed in a competition 
assay at 4°C using mild-acid-treated HLA-A*0201 + B-LCL. The 
binding capacity of the peptides is shown as the concentration of 
peptide needed to inhibit 50% of binding of the fluorescein-labelled 
reference peptide. The affinity of the control HBC core antigen 18-27 
peptide is 0.5 pM.-2Numbers indicate % specific lysis by the relevant 
TIL lines at an E:T ratio of 20:1. Chromium-labelled T2 target cells 
were pre-incubated for 90 min with 1 pM of peptide. Chromium release 
was measured after 5 hr of incubation. Control T2 cells loaded with an 
irrelevant HLA-A*0201 binding peptide were not lysed (3%).
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KTAGQYWQV
KTWAQYWQV
KTWGQYWAV
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F i g u r e  1 -  Target-cell sensitization of gplOO 154-162 alanine-replacement epitopes. Chromium-labelled T2 target cells were pre-incubated for 
1 hr with various amounts of the indicated alanine-substituted epitope analogues. GplOO 154-162-reactive TIL 1200 lymphocytes were added at 
an effector-to - target ratio of 20: L
TABLE n  -  I-ILA-A*0201 BINDING AND TARGET CELL SENSITIZATION 
OF N-TERMINAL ANCHOR-REPLACEMENT EPITOPES
gp'100 154-162 Affinity IC 50 (j-iM) 1 Target-cell lysis by TIL 12002
KTWGQYWQV 1.4 67
KVWGQYWQV 0.8 69
KLWGQYWQV 0.4 65
KMWGQYWQV 0.6 57
KIW'GQYWQV 0.6 68
'Binding of peptides to I~ILA-A*0201 was analyzed in a competition 
assay at 4°C using mild-acid-treated HLA-A*0201+ B-LCL. The 
binding capacity of the peptides is shown as the concentration of 
peptide needed to inhibit 50% of binding of the fluorescein-labelled 
reference peptide-2Numbers indicate % specific lysis by the relevant 
TIL lines at an E:T ratio of 20:1. Chromium-labelled T2 target cells 
were pre-incubated for 90 min with 1 |uM of peptide. Chromium release 
was measured after 5 hr of incubation.
9-mer 154-162 as the most efficient peptide for sensitizing 
HLA~A*0201+ target cells for lysis by the gp 100-reactive TIL 
1200 line (Bakker et al., 1995b). Recently, the gp 100 154-162 
9-mer has been eluted from the cell surface of HLA~A*0201 + 
melanoma cells, and was identified by tandem mass-spectroscopy, 
indicating that this peptide is indeed the nominal epitope endog- 
enously presented in HLA-A*0201 (J. Skipper, personal communi­
cation). To identify amino-acid residues in the epitopes engaged in 
HLA~A*0201 binding and/or TCR interactions, epitope analogues 
were synthesized in which the native amino acid was replaced by 
an alanine residue. The substituted peptides were assayed for 
binding to HLA-A*0201 by means of a cell-bound HLA-A:i:0201- 
binding assay based on competition of a labelled reference peptide 
with the peptides of interest (Van der Burg et ciL, 1995). For the 
gplOO 154—162 epitope analogues, a decreased HLA-A*0201- 
binding capacity was observed for the alanine substitutions at 
positions 3 and 7 (Table I), indicating that these residues are 
important for HLA-A*0201 binding in addition to the anchor 
residues at positions 2 and 9. When the gplOO 154-162 analogues 
were used at micro molar concentrations to sensitize HLA- 
A*0201+ target cells for lysis by gpl 00 154-162-specific CTL, we 
observed a drastic decrease in target-cell lysis for the alanine 
replacements at positions 5, 6 and 7 of the epitope (Table I). This 
demonstrates that the amino acids at these positions are critical 
residues within this epitope for interactions with the TCR.
Subsequently, the epitope analogues that induced reactivity at 
micromolar concentrations were titrated to evaluate their relative 
ability to sensitize T2 target cells for lysis by the relevant CTL (Fig. 
1). In all cases the epitope analogues were similar or inferior to the 
wild-type epitope in their sensitizing capacity, except for the 
alanine substitution at position 8 of the gplOO 154-162 epitope. 
This peptide was able to induce target-cell lysis by gpl 00-reactive 
CTL even at a 10-fold lower concentration.
N-terminal anchor residue replacements in the gplOO 154-162 
epitope result in improved affinity for HLA-A*0201 and in 
enhanced T-cell recognition
Since the gplOO 154-162 epitope has a non-conventional 
N-terminal anchoring residue, we replaced this residue for the 
common HLA-A*0201 anchoring residues V, L, I or M (Ruppert et 
al, 1993). Subsequently, we tested these peptides for HLA- 
A*0201 binding and their ability to sensitize target cells for lysis by 
anti-gplOO 154-162 CTL. All anchor residue replacements in the 
gplOO 154-162 epitope resulted in significantly improved binding 
to HLA-A*0201 (Table II). HLA-A*0201+ target cells loaded with 
these peptides at a concentration of 1 pM were recognized by the 
gplOO 154-162 reactive CTL (Table II). Interestingly, these 
peptides were recognized by TIL 1200 when loaded on target cells 
at 10-fold lower concentrations compared to the wild-type peptide 
(Fig. 2), while the methionine-substituted peptide showed no 
difference. All peptides that were able to sensitize target cells for 
lysis by TIL 1200 at 10-fold lower concentrations, compared to 
wild-type, also displayed a higher HLA-A*0201-binding capacity. 
In addition to the N-terminal anchor substitutions, replacement of a 
polar residue for a hydrophobic residue adjacent to the C-terminal 
anchoring position also resulted in an epitope-analogue with an 
improved HLA-A*0201-binding capacity (KTWGQYWAV), appar­
ently without affecting TCR recognition. These findings demon­
strate that ami no-acid substitutions at different positions within the 
native epitope can result in improved T-cell recognition.
Measurement of MHC class-I peptide complex dissociation rates 
demonstrated that the epitope analogues tested are at least as stable 
as wild-type epitopes (Fig. 3). All peptides that were able to 
enhance T-cell recognition showed a DT50 (the time required for 
50% of the complexes to decay) similar to or higher than that of the 
wild-type epitope (8 hr). Previously, it was shown that peptides 
with DT5o values of >3  hours were immunogenic in HLA- 
A*0201/Kb transgenic mice (van der Burg et a l , 1996). Taken
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KVWGQYWQV
KLWGQYWQV
KMWGQYWQV
KIWGQYWQV
peptide concentration (|aM)
F ig u re  2 -Target-cell sensitization of gplOO 154-162 N-terminal anchor-replacement epitopes. Chromium-release experiments were 
performed as in Figure 1. GplOO 154-162-reactive TIL 1200 lymphocytes were used to assay target-cell sensitization by the gplOO 154-162 
analogues at an effector-to-target ratio of 20:1.
KTWGQYWQV
KTWGQYWAV
KLWGQYWQV
KVWGQYWQV
KIWGQYWQV
hours
F ig u r e  3 -  HLA-Aîi:0201-peptide complex stability of gplOO 154-162 epitope analogues. The dissociation rate of HLA-A*0201-peptide 
complexes was measured using emetine pre-treated HLA-A *0201 + B-LCL. After mild-acid treatment, empty cell-surface HLA-A*0201 
molecules were loaded at room temperature and the cells were then placed at a temperature of 37°C. The decay of cell-surface HLA-A*0201 
molecules was analyzed by flow cytometry. The dissociation rate is depicted as the time required for 50% of the MHC class-I-peptide complexes to 
decay at 37°C.
together, these data indicate that the immunogenicity of the gplOO 
154-162 epitope analogues may be similar to, or higher than, that 
of wild-type gplOO 154-162.
Immunogenicity of gplOO 154-162 epitope analogues in 
HLA-A*0201/kb transgenic mice
In order to determine the in vivo immunogenicity of the gplOO 
154-162 epitope analogues whose MHC class-I binding affinity 
and dissociation rate were measured, HLA-A*0201/Kb transgenic 
mice were vaccinated with the gplOO 154-162 wild-type epitope, 
with the epitope analogues KTWGQYWAV, KVWGQYWQV, 
KLWGQYWQV or KIWGQYWQV, or with a control peptide 
(HBVcore 18-27; FLPSDDFPSV). The generation of these trans­
genic mice (Vitiello et ah, 1991) and their use in analyzing in vivo 
immunogenicity have been described (Sette et ah, 1994). It has 
been shown that there exists an extensive overlap between the 
T-cell repertoires of HLA-A*0201/Kb transgenic mice and HLA- 
A*0201 + humans, supporting the use of HLA-transgenic mice to 
identify human CTL epitopes (Wentworth et ah, 1996). As shown 
in Figure 4, the gplOO 154-162 epitope analogues KTWGQY­
WAV, KVWGQYWQV and KLWGQYWQV very efficiently 
induced a CTL response. To a lesser extent, the epitope analogue 
KIWGQYWQV and the wild-type gplOO 154-162 were also able
to elicit a CTL response. Bulk CTL derived from mice vaccinated 
with the gp'100 154-162 epitope analogues specifically lysed Jurkat 
A*0201/Kb cells loaded with both the peptide used for vaccination 
and the wild-type epitope. Interestingly, CTL bulk cultures raised 
against the epitope analogues all recognized target cells pulsed with 
the wild-type epitope as well as, or better than, target cells pulsed 
with epitope analogues used for vaccination. Thus, all gplOO 
154-162 epitope analogues tested were immunogenic in HLA- 
A:,:0201/Kb transgenic mice, and elicited CTL displaying cross­
reactivity with the native gplOO 154-162 epitope.
In vitro induction o f gp100 154-162 epitope-analogue-specific 
human CTL displaying cross-reactivity with endogenously 
HLA -A *02 01-p resented w ild-type gp 100 154-162
Next we performed in vitro CTL induction assays to assess 
whether, within the T-cell repertoire of H L A -A * 0 2 0 1 p recu rso r T 
lymphocytes of healthy donors were present and capable of 
recognizing gplOO 154-162 epitope analogues. In order to achieve 
this, we initiated cultures of peptide-loaded dendritic cells together 
with autologous responder T lymphocytes as described (Bakker et 
ah, 1995a). After several rounds of restimulation, responder T cells 
were tested for their cytotoxic activity (Fig. 5). All bulk CTL 
populations raised against the gplOO 154-162 epitope analogues
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F i g u r e  4  ~ lmmunogenicity o f  gplOO 154-162 epitope-analogues in HLA-A*0201/Kb transgenic mice. Bulk CTL obtained frprn immunized 
mice were tested for lytic activity using chromium-labelled Jurkat A2/Kb target cells that were pre-incubated with no peptide and IO^ iM wild-type 
gplOO 154-162 or 10 pM of the epitope analogue used to immunize the mice. For each peptide the mean specific lysis of bulk CTL of the 
responding mice is shown. Standard deviations never exceeded 15% of the mean value. One representative experiment out of 2 is shown.
KTWGQYWAV, KVWGQYWQV, KLWGQYWQV and KIW­
GQYWQV efficiently lysed HLA-A*0201+ T2 target cells incu­
bated with the peptides used for CTL induction. Only low 
background lysis was observed in the presence of an irrelevant 
peptide. In addition, these gplOO 154—162 epitope-analogue- 
reactive CTL efficiently lysed T2 target cells incubated with 
wild-type gp 100 154-162, To address the question of whether these 
CTL responder populations could also recognize endogenously 
processed and presented wild-type epitope, we performed chro- 
mium-release experiments using HLA-A*0201+ melanoma cell 
lines BLM and Mel 624 as targets. BLM cells have lost their 
expression of the gplOO antigen, at both the protein and the mRNA 
levels. As shown in Figure 6 , all peptide-induced CTL cultures 
lysed the anti gen-expressing Mel 624 cells, whereas no or back­
ground lysis was observed against antigen-negative BLM cells. 
TNF release by the anti-gplOO 154—162 analogue CTL further 
demonstrated the reactivity of these CTL with endogenously 
presented wild-type gplOO 154-162 (data not shown). These data 
show that the 4 different CTL cultures induced using gplOO 
154-162 epitope-analogue-loaded dendritic cells, all recognized 
the native gplOO 154-162 epitope endogenously processed and 
presented by HL A-A *0201* Mel 624 cells.
DISCUSSION
Since MHC class-I affinity and stability of the peptide-MHC 
complex are important parameters determining the immunogenic- 
ity of an MHC class-I-presen ted epitope, we explored the possibil­
ity of improving the capacity of a melanocyte differentiation 
antigen-derived epitope to bind to HLA-A*0201 without affecting 
interactions with the TCR. Detailed analysis of the gplOO 154-162 
epitope using alanine substitutions revealed that amino acids at 
positions or 5 to 7 are critical residues for TCR recognition. These
data are in line with X-ray crystallography studies of the HLA- 
A*0201 molecule (Saper etaL, 1991), implying a role for the more 
permissive residues at positions 4 and 5 of the peptide oriented 
towards the outside of the MHC molecule, as prominent TCR 
contact sites. Our data confirm and extend these findings and 
demonstrate that, for HLA-A*G201, the amino acids at positions 6 
and 7 of the gplOO 154-162 epitope do not only interact with 
secondary pockets in the MHC peptide-binding cleft, but are also 
critical residues for TCR interaction (Ruppert et ai, 1993; Madden 
et a i , 1993).
The alanine substitution at position 8 in the gplOO 154-162 
epitope, KTWGQYWAV, resulted in a peptide that displayed 
increased HLA-A*0201 affinity. Moreover, this epitope analogue 
was recognized by gp 100-reactive CTL at 10-fold lower concentra­
tions compared to the native epitope. These data demonstrate that 
amino-acid substitutions at a non-anchor position can result in 
increased MHC class-I affinity and T-cell recognition. Similar 
findings were reported for the HLA-A*0201-restricted HIV-1 
reverse transcriptase 476-484 epitope, in which substitutions at the 
first position of the peptide resulted in an increased stability of the 
peptide-MHC complex at the cell surface (Pogue et ai, 1995).
By N-terminal anchor replacements with V, L, M or I towards the 
HLA-A*0201 binding motifs, we set out to identify epitope 
analogues with improved HLA-A*0201-binding capacity that were 
still recognized by wild-type epitope-reactive CTL. For the gplOO 
154-162 epitope we obtained, in addition to the alanine-substituted 
analogue KTWGQYWAV, 3 anchor-substituted epitope analogues 
KVWGQYWQV, KLWGQYWQV, and KIWGQYWQV, with im­
proved HLA-A!,i0201-binding capacity that were recognized by 
anti-gplOO CTL at 10-fold lower concentrations compared to the 
wild-type epitope. In vivo immunization experiments using HLA- 
A*0201/Kb transgenic mice demonstrated that these epitope ana­
logues were immunogenic, resulting in the induction of murine
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CTL reactive with both the epitope analogues and the native 
epitope. The immunogenicity of the epitope analogues was ex­
pected since the stability of the peptide-MHC complex of both the 
epitope analogues and the native epitope was comparably high. 
Therefore, our results confirm previous data demonstrating that 
peptides with low MHC class-I-peptide complex dissociation rates 
can effectively induce CTL responses (van der Burg et al, 1996),
In vitro CTL induction experiments using donor-derived PBL 
demonstrated that epitope-analogue-specific CTL could be ob­
tained displaying cross-reactivity with tumor cells endogenously 
presenting the wild-type epitope. In addition to T lymphocytes 
reacti ve with the wild-type epitope, the T-cell repertoire of healthy 
donors apparently also contains T cells reactive with the gplOO 
154-162 epitope analogues. Analysis of TCR usage of cloned CTL 
reactive with the different gplOO 154-162 epitope analogues and 
with wild-type gplOO 154-162, which is currently under investiga­
tion, will be informative of the spectrum of the T-cell repertoire that 
can be used to induce CTL reactivity towards the wild-type epitope. 
Previously, it was observed that the repertoire of CTL directed 
against the MAGE-1 161-169 antigenic tumor peptide (HLA- 
A *010 .1) in a melanoma patient can be diverse in terms of both 
antigen recognition and TCR usage (Romero et al, 1995). Analy­
ses of TCR repertoires specific for a variety of antigenic peptides 
presented in MHC class-I molecules have shown that they can be 
either relatively homogeneous (Kalams et al, 1994; Lehner et al, 
1995) or highly diverse (Taylor et al, 1990; Cole et al, 1994). Thus 
far it is not clear what determines the degree of diversity in the TCR 
repertoires. It has been proposed that limited TCR repertoires 
represent “public” CTL specificities, that can be reproducibly 
isolated from different individuals in experimental models (Cibotti 
et al, 1994). In addition to these dominant public repertoires, 
“ private” TCR repertoires can exist that are more diverse and that 
differ for each individual. It is tempting to speculate that, in the case 
of self-antigens, public CTL specificities are rendered non­
functional due to tolerizing mechanisms while the private TCR 
repertoire is unaffected. With respect to immunotherapy of cancer,
potential activation of multiple specificities in the private T-cell 
repertoire against an antigenic tumor epitope using epitope ana­
logues may stimulate immunoreactivity after vaccination, resulting 
in an anti-tumor response.
In summary, we describe here the identification of epitope 
analogues of the gplOO 154-162 epitope with potentially improved 
immunogenicity, that were obtained by amino-acid substitutions in 
both anchor and non-anchor positions in the native epitope. In 
addition to the gplOO 154-162 epitope, we explored this methodol­
ogy to select analogues for the low HLA-A*0201 -affinity MART-1 
27-35 epitope (data not shown). Recently, it was shown for 2 other 
gplOO-derived epitopes, located at positions 209-217 and 280- 
288, that amino-acid substitutions at anchoring positions may 
result in epitope analogues with improved immunogenicity 
(Parkhurst e ta l ,  1996). Using these epitope analogues, the authors 
demonstrated an enhanced induction of melanoma-reactive CTL 
from HLA-A:i;0201 + melanoma patients compared to the native 
epitopes. Employment of “ improved” epitopes in immunotherapy 
protocols may increase the amount of peptide-MHC complexes at 
the cell surface of antigen-presenting cells in vivo, and may thus 
result in enhanced priming of antigen-specific CTL. Apart from 
their potential in cancer immunotherapy, the use of epitope 
analogues with improved immunogenicity may contribute to the 
development of CTL-epitope-based vaccines in chronic viral 
disease.
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